12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tivantinib: Additional Phase I data

Data from 16 melanoma patients in an extension cohort of an open-label, dose-escalation, U.S. and Italian Phase I trial showed that twice-daily 360 mg oral tivantinib plus Nexavar sorafenib led an overall response rate (ORR) of 25%, including 1 complete response and 3 partial responses, plus 3 cases of stable disease. Median progression-free survival (PFS) was 5.3 months. In 8 patients...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >